GYG Gyg Plc

RNS Number:3914Y
Gyrus Group PLC
6 February 2001


GYRUS GROUP PLC
("Gyrus" or the "Group")


GYRUS ANNOUNCES RE-LAUNCH OF THE VERSAPOINT HYSTEROSCOPIC SYSTEM

*  Following regulatory clearance received today from the FDA, Gyrus announces
that the VersaPoint Hysteroscopic System will be re-launched in Europe and the
US by their marketing partner Gynecare, a division of Ethicon Inc a Johnson &
Johnson company, during the month of February.

*  The timing of the re-launch is in line with the Company's expectations
announced in November 2000.

Commenting on this announcement Dr Mark Goble, Gyrus Group CEO, said:

"Throughout the process of returning VersaPoint to the market the enthusiastic
commitment of everybody concerned, from eminent gynaecologist to lab
technician, to resolving what is a complex clinical problem has been
exemplary.  I am particularly pleased that we have put this issue behind us
prior to announcing our Results on 8th March."


GYRUS ANNOUNCES RE-LAUNCH OF THE VERSAPOINT HYSTEROSCOPIC SYSTEM

Following regulatory clearance received today from the FDA, Gyrus announces
that the VersaPoint Hysteroscopic System will be re-launched in Europe and the
US by their marketing partner Gynecare, a division of Ethicon Inc a Johnson &
Johnson company, during the month of February.

In September 2000, Gynecare voluntarily withdrew the VersaPoint System
(excluding the generators) from the market following a small number of
suspected cases of air or gas embolism which were reported to have occurred
during hysteroscopic myomectomy.

Following review of these cases by an international panel of experts it was
determined that the principal cause of these events was not related to the
VersaPoint technology but to other techniques employed during hysteroscopic
surgery.  The panel developed a series of recommendations for inclusion in the
product labelling to improve these techniques and will also be publishing
their findings in scientific journals.

These recommendations have now been reviewed and cleared by the FDA.  Shipment
of products with the revised labelling has now commenced to support the
re-launch in February in line with the Company's expectations announced in
November 2000.

Of the 1,200 VersaPoint user sites only two generators were returned,
demonstrating a sustained belief in the technology.  Users have also indicated
that cases have been postponed awaiting re-introduction.  The Company
anticipate that the financial impact will be contained to a loss of one
quarters sales as estimated at the time of the original announcement, an
impact that will be absorbed by performance in other sectors of the business.

Commenting on this announcement Dr Mark Goble, Gyrus Group CEO, said:

"Throughout the process of returning VersaPoint to the market the enthusiastic
commitment of everybody concerned, from eminent gynaecologist to lab
technician, to resolving what is a complex clinical problem has been
exemplary.  I am particularly pleased that we have put this issue behind us
prior to announcing our results on 8th March."


ENQUIRIES


Jean Garon PR                                   
Tel: (01628) 483040
Fax: (01628) 486796
E-Mail: jean@garonpr.demon.co.uk


YEAR END RESULTS PRESENTATION

Gyrus Group PLC will be announcing their Results on the morning of 8th March
2001.  A presentation for Analysts and Brokers is being held at WestLB
Panmure, 33 Gracechurch Street, London at 11.30am.  Please call Jean Garon PR
on (01628) 483040 if you would like to attend.


With Compliments
Jean Garon PR
Tel: (01628) 483040
Fax: (01628) 486796
E-Mail: jean@garonpr.demon.co.uk


Information in this announcement may include forward looking statements which
embrace risk and uncertainties.  However all information included in this text
is based on information available to our client at the time of issue.  These
statements are not guarantees of future performance and actual results could
differ materially from current expectations.

Gyg (LSE:GYG)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

Gyg (LSE:GYG)
Historical Stock Chart
Von Jul 2023 bis Jul 2024